ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
13 announcements
Promoters sold a total of 15.12 lakh shares via open market transactions, aggregating to ₹106.43 Crore.
Aarti Pharmalabs reported directorate changes, including Shri Rashesh Gogri's appointment as Managing Director, Smt. Hetal Gogri Gala's re-designation, and the cessation of Shri Rajendra Gogri.
Aarti Pharmalabs promoters sold a net 29.03 lakh shares, reducing their stake from 42.88% to 39.66%. No transaction value is disclosed in this periodic SAST filing.
7th AGM presentation for Aarti Pharmalabs. Reported Standalone FY26 Revenue of INR 1,798 Cr with 23% EBITDA margin; Consolidated revenue down 14% YoY to INR 1,819 Cr.
Aarti Pharmalabs conducted its 7th Annual General Meeting on September 22, 2026, to transact ordinary and special business, with voting results to follow.
Promoter Group entities, Safechem Enterprises and Relacion Trusteeship, sold 1,19,400 shares of Aarti Pharmalabs in the open market for a total of ₹10.43 Crore.
Safechem Enterprises Private Limited, part of the promoter group, sold 30,000 equity shares of Aarti Pharmalabs Ltd in the open market.
Aarti Pharmalabs received an order from the Superintendent of Stamps, Gujarat, demanding ₹59.50 Crore for stamp duty and penalties related to a past demerger scheme.
APL reported robust Q1FY27 consolidated revenue of INR 5,358 Mn (+38.7% YoY) with EBITDA margins improving to 24.75%. Management is focusing on high-margin CDMO and Xanthine capacity expansion.
Aarti Pharmalabs Ltd reported revenue from operations of ₹535.8 Cr (+38.7% YoY) and net profit of ₹76.1 Cr (+65.4% YoY) for Q1 FY27.
Aarti Pharmalabs reported Q4 FY26 revenue of ₹580 Cr (+9% YoY) but PAT declined to ₹62 Cr from ₹89 Cr due to higher costs and forex losses.
Aarti Pharmalabs reported FY26 standalone revenue of INR 17,976 Mn with a 23% EBITDA margin. Strategy focuses on CDMO expansion and backward integration for Xanthine derivatives.
Aarti Pharmalabs Ltd reported revenue from operations of ₹582.6 Cr (+3.3% YoY) and net profit of ₹61.1 Cr (-30.8% YoY) for Q4 FY26.